As there is a Lung Cancer Study Day coming up on 18th September, we thought it might be useful to compile a list of resources for NHS staff treating patients with Lung Cancer.
Many links will ask you to log in with OpenAthens to access the full resource, if you have any trouble accessing something, please get in touch with your Trust library.
Christie Research Repository
Recent research outputs from the staff and students at The Christie NHS Foundation Trust.
Building the case for comprehensive hospital-based tobacco addiction services: applying the Ottawa Model to the City of Manchester. (Evison, 2018)
Current and future therapeutic approaches for the treatment of small cell lung cancer. (Rossi et al, 2018)
Implementing lung cancer screening: baseline results from a community-based ‘Lung Health Check’ pilot in deprived areas of Manchester. (Crosbie, 2018)
The impact of the UK Government ‘two week rule’ (TWR) on lung cancer stage and 5-year survival – a decade of experience from the Royal Marsden Hospital (RMH). (Dolly et al, 2018)
Whole brain radiotherapy in metastatic non-small cell lung cancer: an audit of current practice. – Conf Abstract (Clarke et al, 2018)
Advanced Radiotherapy Technologies Network in the UK (ART-NET) – focus on lung cancer (Brown et al, 2018)
Safety of immunotherapy in elderly lung cancer patients: interim data from the ELDERS study. (Gomes et al, 2018)
Factors influencing timely management of stage I non-small cell lung cancer (NSCLC) in the multidisciplinary team meeting (MDT). (Queen et al, 2018)
Open Access
PDFs to download on the Macmillan site
Developing a complex intervention to support timely engagement with palliative care for patients with advanced cancer in primary and secondary care in the UK: a study protocol. (Hackett et al, 2018)
Can improving working partnerships with primary care prevent avoidable emergency admissions for patients with lung cancer? (Eaton et al, 2018)
Centralising specialist cancer surgery services in England: survey of factors that matter to patients and carers and health professionals. (Melnychuk et al, 2018)
eBooks
Fast Facts: Non-Small-Cell Lung Cancer [DawsonEra ebook]
Handbook of Lung Cancer and Other Thoracic Malignancies [DawsonEra ebook]
Lung Cancer [DawsonEra ebook]
Books
Available in the Library, Department 60
NICE
All NICE publications on lung cancer
UptoDate
Lung cancer incidence among young men and women (May 2018, via UptoDate)
Lung cancer incidence has historically been higher in men than women. However, a study using 20 years of data from a United States cancer registry found that, although the overall incidence of lung cancer has generally decreased among both men and women 30 to 54 years old, the incidence of lung cancer in non-Hispanic whites in the 30- to 49-year-old age group is now higher in women than in men [77]. This reversal in trends is not fully explained by gender differences in smoking behaviors. More study is required to understand the reasons for the relatively higher incidence of lung cancer among young women compared with young men. (See “Women and lung cancer”, section on ‘Comparison of men and women’.)
Atezolizumab plus bevacizumab and chemotherapy in advanced, nonsquamous NSCLC (July 2018, via UptoDate)
Although combinations of chemotherapy and immunotherapy are being explored for advanced non-small cell lung cancer (NSCLC), previous trials have typically excluded patients with ALK or EGFR driven cancers. In the IMpower 150 trial, among patients with advanced, chemotherapy-naïve, nonsquamous NSCLC, addition of the anti-PD-L1 antibody atezolizumab to bevacizumab and a platinum-based chemotherapy doublet improved progression-free survival, a benefit that was also observed in the 14 percent whose tumors had activating ALK or EGFR mutations [75]. Based on these new data, the combination of immunotherapy and chemotherapy may be considered for those with driver-mutated nonsquamous NSCLC who have progressed on available targeted therapies, although this remains an off-label indication.
(See “Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer”, section on ‘Resistance to other ALK inhibitors’.)
Overview of approach to lung cancer survivors
Complementary and alternative therapies for cancer
EJournals
Lung Cancer [ClinicalKey eJournal]
Journal of Thoracic Oncology
Clinical Lung Cancer
Thoracic Cancer
Lung Cancer International
More information about the forthcoming study day can be found here – the event aims to explore redefined care for lung cancer patients from a multi-disciplinary context. Attendees will explore updates regarding current genetic approaches to treatment, and the importance of support from all members of the team.